X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9403) 9403
Book Chapter (115) 115
Magazine Article (6) 6
Conference Proceeding (5) 5
Newspaper Article (5) 5
Publication (3) 3
Dissertation (2) 2
Book / eBook (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rituximab (8414) 8414
humans (7941) 7941
science & technology (7283) 7283
life sciences & biomedicine (7180) 7180
female (4505) 4505
male (4499) 4499
middle aged (3828) 3828
adult (3103) 3103
aged (3044) 3044
antibodies, monoclonal, murine-derived (2778) 2778
treatment outcome (2705) 2705
hematology (2568) 2568
oncology (2382) 2382
antineoplastic combined chemotherapy protocols - therapeutic use (2340) 2340
antibodies, monoclonal - therapeutic use (1697) 1697
antibodies, monoclonal - administration & dosage (1681) 1681
antibodies, monoclonal, murine-derived - administration & dosage (1665) 1665
cyclophosphamide - administration & dosage (1550) 1550
lymphomas (1381) 1381
aged, 80 and over (1252) 1252
antineoplastic combined chemotherapy protocols - administration & dosage (1230) 1230
antibodies, monoclonal, murine-derived - therapeutic use (1214) 1214
vincristine - administration & dosage (1174) 1174
care and treatment (1138) 1138
rituximab - administration & dosage (1125) 1125
doxorubicin - administration & dosage (1102) 1102
retrospective studies (1051) 1051
prednisone - administration & dosage (1018) 1018
chemotherapy (1015) 1015
lymphoma, large b-cell, diffuse - drug therapy (953) 953
medicine & public health (950) 950
antineoplastic agents - therapeutic use (943) 943
cancer (941) 941
prognosis (897) 897
rituximab - therapeutic use (882) 882
remission induction (872) 872
patients (860) 860
young adult (854) 854
immunologic factors - therapeutic use (842) 842
adolescent (833) 833
disease-free survival (812) 812
immunology (774) 774
transplantation (773) 773
rheumatology (769) 769
abridged index medicus (757) 757
lymphoma (744) 744
recurrence (743) 743
follow-up studies (737) 737
antineoplastic combined chemotherapy protocols - adverse effects (727) 727
antineoplastic agents - administration & dosage (725) 725
drug therapy (722) 722
immunosuppressive agents - therapeutic use (680) 680
antibodies, monoclonal - adverse effects (664) 664
antibodies, monoclonal, murine-derived - adverse effects (660) 660
drug administration schedule (651) 651
immunotherapy (651) 651
cyclophosphamide (640) 640
antineoplastic agents (631) 631
hemic and lymphatic diseases (629) 629
monoclonal antibodies (625) 625
risk factors (620) 620
analysis (612) 612
antimitotic agents (599) 599
lymphoma, b-cell - drug therapy (554) 554
health aspects (551) 551
leukemia, lymphocytic, chronic, b-cell - drug therapy (547) 547
combined modality therapy (537) 537
research (534) 534
animals (527) 527
lymphoma, non-hodgkin - drug therapy (521) 521
cyclophosphamide - therapeutic use (519) 519
immunologic factors - administration & dosage (514) 514
time factors (514) 514
drug therapy, combination (512) 512
rheumatoid arthritis (499) 499
lymphocytes b (492) 492
pharmacology & pharmacy (491) 491
clinical trials (482) 482
child (467) 467
lymphoma, follicular - drug therapy (464) 464
immune system diseases (462) 462
general & internal medicine (461) 461
medicine, general & internal (447) 447
immunoglobulins (445) 445
b-lymphocytes - immunology (433) 433
rituximab - adverse effects (433) 433
lymphoma, large b-cell, diffuse - pathology (424) 424
survival rate (424) 424
antigens, cd20 - immunology (419) 419
survival analysis (413) 413
arthritis, rheumatoid - drug therapy (408) 408
antineoplastic agents - adverse effects (406) 406
corticosteroids (401) 401
vidarabine - analogs & derivatives (390) 390
internal medicine (385) 385
antirheumatic agents - therapeutic use (374) 374
prospective studies (372) 372
pediatrics (371) 371
neoplasm staging (369) 369
prednisone - therapeutic use (365) 365
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9112) 9112
Japanese (217) 217
German (90) 90
French (88) 88
Spanish (76) 76
Russian (48) 48
Chinese (39) 39
Italian (21) 21
Hungarian (20) 20
Portuguese (13) 13
Czech (7) 7
Polish (7) 7
Norwegian (6) 6
Danish (4) 4
Dutch (3) 3
Finnish (3) 3
Korean (2) 2
Turkish (2) 2
Bosnian (1) 1
Croatian (1) 1
Hebrew (1) 1
Persian (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 06/2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 75, pp. 195 - 203
Abstract Purpose Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor... 
Hematology, Oncology and Palliative Medicine | CNS relapse | Secondary CNS involvement | Prognosis | CNS prophylaxis | PET/CT | Diffuse large B-cell lymphoma | CNS-IPI | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Immunotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Central Nervous System Neoplasms - secondary | Young Adult | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Central Nervous System Neoplasms - prevention & control | Aged, 80 and over | Vincristine - administration & dosage | Adult | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Neoplasm Recurrence, Local - prevention & control | Risk Factors | Rituximab | Treatment Outcome | Combined Modality Therapy | Lymphoma, Large B-Cell, Diffuse - prevention & control | Positron Emission Tomography Computed Tomography | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Adolescent | Aged | Medicine, Experimental | Medical research | Care and treatment | Lymphomas | PET imaging | Biomedical engineering | Analysis | Oncology, Experimental | Research | Cancer | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 394 - 401
Summary Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis... 
Burkitt leukaemia | children | chemotherapy | rituximab | Burkitt lymphoma | Rituximab | Chemotherapy | Children | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Index Medicus | Burkitt Leukaemia | Burkitt Lymphoma | adolescents
Journal Article
Blood, ISSN 1528-0020, 02/2015, Volume 125, Issue 9, pp. 1403 - 1410
Journal Article